Anchor Therapeutics, Inc.

Attachments

2010: In early September Ortho-McNeil-Janssen Pharmaceuticals, a unit of J&J, stepped up with a discovery deal packed with $480 million in milestones and an undisclosed upfront.(2010)
Anchor believes its pepducin approach--using short peptides bound to a hydrophobic lipid moiety--can penetrate to the receptor on the inner cell membrane, doing a much better job than most small molecules which target and modulate GPCR signaling.
Anchor Therapeutics, Inc., closed a $10M Series B financing. Participants include TVM Capital, HealthCare Ventures and Novartis
Anchor Therapeutics, Inc.: Series B $10M (2010)
Anchor, originally named Ascent, quickly executed its first pact with the Novartis Option Fund, a $200 million licensing option deal that could be picked up "sooner rather than later," says CEO Rick Jones.
Cambridge, Massachusetts
CEO: Frederick Jones
Founded 2008
G-protein coupled receptors (GPCRs) cell signaling proteins play a leading role in the fight against hundreds of diseases in big categories like inflammation, cancer, cardiovascular and metabolic ailments.
Preclinical-stage biopharmaceutical company focused on peptides to modulate G-protein coupled receptors in oncology, CV and infl
Venture backers: TVM Capital, HealthCare Ventures and the Novartis Option Fund